{"id":206996,"date":"2010-01-21T03:40:32","date_gmt":"2010-01-21T08:40:32","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=59418"},"modified":"2010-01-21T03:40:32","modified_gmt":"2010-01-21T08:40:32","slug":"a-baldness-update-from-histogen-sequenom-agrees-to-settle-a-suit-the-life-sciences-job-outlook-improves-more-san-diego-life-sciences-news","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/206996","title":{"rendered":"A Baldness Update from Histogen; Sequenom Agrees to Settle a Suit; the Life Sciences Job Outlook Improves &amp; More San Diego Life Sciences News"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Roundup\/\">Roundup<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/Life-Sciences\/\">Life Sciences<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/innovation-economy\/\">Innovation Economy<\/a><\/div>\n<p>\t\t<strong>Denise Gellene wrote:<\/strong><\/p>\n<p>There were new developments over the past week in some big ongoing stories.<\/p>\n<p>&#8212;<strong>Histogen<\/strong> CEO Gail Naughton told Bruce <a href=\"http:\/\/www.xconomy.com\/san-diego\/2010\/01\/15\/is-histogen-hair-to-stay-amid-patent-lawsuit-that-is-mane-event-ceo-updates-plans-to-advance-its-hair-regrowth-treatment\/\">the San Diego-based biotech expects to report results from a one-year follow-up of study of its experimental baldness treatment by the end of this month<\/a>. Histogen plans additional clinical studies on volunteers with male-pattern baldness&#8212;all of them in Asia. (Sorry, guys.)<\/p>\n<p>&#8212; The job market in San Diego&#8217;s life sciences industry is showing signs of, well, life. <a href=\"http:\/\/www.xconomy.com\/san-diego\/2010\/01\/19\/san-diego-biotechs-seem-poised-to-start-hiring-but-chemists-will-face-a-tough-time\/\"><strong>Recruiter Meredith Dow of Proven<\/strong> Inc. told me that layoffs appear to have slowed and some biotech startups are beginning to talk about hiring<\/a>. Some occupations have a brighter outlook than others, she noted.<\/p>\n<p>&#8212;<strong>Illumina <\/strong>(NASDAQ: <a href=\"http:\/\/finance.yahoo.com\/q?s=ILMN\">ILMN<\/a>), <a href=\"http:\/\/www.xconomy.com\/san-diego\/2010\/01\/14\/new-machine-from-san-diegos-illumina-intensifies-race-for-faster-cheaper-genome-decoder\/\">the San Diego-based tools company, introduced a machine that can decode an individual&#8217;s genome for under $10,000<\/a> in a bid to establish the company&#8217;s leadership in the gene-sequencing business.<\/p>\n<p>&#8212;<strong>Sequenom<\/strong> (NASDAQ: <a href=\"http:\/\/finance.yahoo.com\/q?s=SQNM\">SQNM<\/a>) <a href=\"http:\/\/www.xconomy.com\/san-diego\/2010\/01\/15\/sequenom-settles-shareholder-lawsuits-for-14m-plus-stock\/\">agreed to pay shareholders $14 million from its insurance proceeds and issue them new shares worth a 9.95 percent stake in the company to settle a class action suit<\/a>. The settlement, which requires court approval, would resolve one problem related to what the company characterized as the mishandling of data from a clinical trial involving the company&#8217;s experimental Down syndrome test.<\/p>\n<p>&#8212;<a href=\"http:\/\/www.xconomy.com\/san-diego\/2010\/01\/14\/crinetics-enters-collaboration-agreement-with-ferring-research-institute\/\"><strong>Crinetics Pharmaceuticals<\/strong>, a San Diego startup developing biosensors for drug discovery applications, signed a collaboration agreement with the Ferring Research Institute<\/a>, the peptide research center established in San Diego by Ferring Pharmaceuticals.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/san-diego\/2010\/01\/21\/a-baldness-update-from-histogen-sequenom-agrees-to-settle-a-suit-the-life-sciences-job-outlook-improves-more-san-diego-life-sciences-news\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20A%20Baldness%20Update%20from%20Histogen;%20Sequenom%20Agrees%20to%20Settle%20a%20Suit;%20the%20Life%20Sciences%20Job%20Outlook...%20http:\/\/xconomy.com\/?p=59418\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/san-diego\/2010\/01\/21\/a-baldness-update-from-histogen-sequenom-agrees-to-settle-a-suit-the-life-sciences-job-outlook-improves-more-san-diego-life-sciences-news\/&#038;t=A%20Baldness%20Update%20from%20Histogen;%20Sequenom%20Agrees%20to%20Settle%20a%20Suit;%20the%20Life%20Sciences%20Job%20Outlook%20Improves%20&#038;%20More%20San%20Diego%20Life%20Sciences%20News\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/san-diego\/2010\/01\/21\/a-baldness-update-from-histogen-sequenom-agrees-to-settle-a-suit-the-life-sciences-job-outlook-improves-more-san-diego-life-sciences-news\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=A+Baldness+Update+from+Histogen%3B+Sequenom+Agrees+to+Settle+a+Suit%3B+the+Life+Sciences+Job+Outlook+Improves+%26%23038%3B+More+San+Diego+Life+Sciences+News&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fsan-diego%2F2010%2F01%2F21%2Fa-baldness-update-from-histogen-sequenom-agrees-to-settle-a-suit-the-life-sciences-job-outlook-improves-more-san-diego-life-sciences-news%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=a389a906f0a60b7013a2f825c7c07da1&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=a389a906f0a60b7013a2f825c7c07da1&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/a.rfihub.com\/eus.gif?eui=2218\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/TJ7UkMz9_jXGnNqeXKWfJccXBjA\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/TJ7UkMz9_jXGnNqeXKWfJccXBjA\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/TJ7UkMz9_jXGnNqeXKWfJccXBjA\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/TJ7UkMz9_jXGnNqeXKWfJccXBjA\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/aNo861MEYuc\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roundup, Life Sciences, Innovation Economy Denise Gellene wrote: There were new developments over the past week in some big ongoing stories. &#8212;Histogen CEO Gail Naughton told Bruce the San Diego-based biotech expects to report results from a one-year follow-up of study of its experimental baldness treatment by the end of this month. Histogen plans additional [&hellip;]<\/p>\n","protected":false},"author":2918,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-206996","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/206996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/2918"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=206996"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/206996\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=206996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=206996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=206996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}